Inactive Instrument

Cynapsus Therapeutics Inc Share Price Toronto S.E.

Equities

End-of-day quote Toronto S.E. Other stock markets
- ^CAD	-

03-11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
01-29	CoTec Holdings Outlines Key Targets For 2024	MT

Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	03-11	MT
CoTec Holdings Outlines Key Targets For 2024	01-29	MT
Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	01-03	MT
Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	10/10/23	MT
Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	10/10/23	MT
CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	02/10/23	MT
Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	14/09/23	MT
CoTec Holdings, Mkango To Form US Joint Venture	14/09/23	MT
Kings Chapel Increases Stake In CoTec Holdings	30/06/23	MT
CoTec Holdings Up 11% as it Raises Its Stake in MagIron LLC as Its Holding is now Worth More Than its Stock-Market Value	19/06/23	MT
Mako Mining Commences Work at Las Conchitas; Processing of Material Expected in July	19/06/23	MT
Mkango Up 9% In Mid-Afternoon UK Trade As Maginito Moves To Buy Pioneering Rare Earth Magnet Recycler HyProMag	16/05/23	MT
CoTec Holdings Corp. Increases Interest in MagIron; CTH Lost Near 11% on Friday	01/05/23	MT
CoTec Holdings Jumps 12% As Reports Maiden Annual Profit For 2022	21/04/23	MT
CoTec Holdings Reports Maiden Annual Profit For 2022	21/04/23	MT

Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	31/08/16	PU
Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	29/08/16	GL
Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	15/08/16	GL
Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	12/08/16	GL
Cynapsus Therapeutics : Reports Second Quarter 2016 Financial Results and Recent Developments	10/08/16	GL

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B